AU2001273063A1 - Stabilized interleukin 2 - Google Patents
Stabilized interleukin 2Info
- Publication number
- AU2001273063A1 AU2001273063A1 AU2001273063A AU7306301A AU2001273063A1 AU 2001273063 A1 AU2001273063 A1 AU 2001273063A1 AU 2001273063 A AU2001273063 A AU 2001273063A AU 7306301 A AU7306301 A AU 7306301A AU 2001273063 A1 AU2001273063 A1 AU 2001273063A1
- Authority
- AU
- Australia
- Prior art keywords
- interleukin
- stabilized
- stabilized interleukin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
- A61K38/2013—IL-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/605,577 | 2000-06-28 | ||
US09/605,577 US6689353B1 (en) | 2000-06-28 | 2000-06-28 | Stabilized interleukin 2 |
PCT/US2001/020675 WO2002000243A2 (en) | 2000-06-28 | 2001-06-27 | Stabilized interleukin 2 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2001273063A1 true AU2001273063A1 (en) | 2002-01-08 |
Family
ID=24424265
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001273063A Abandoned AU2001273063A1 (en) | 2000-06-28 | 2001-06-27 | Stabilized interleukin 2 |
Country Status (24)
Country | Link |
---|---|
US (1) | US6689353B1 (en) |
EP (1) | EP1370280B1 (en) |
JP (3) | JP5522878B2 (en) |
KR (1) | KR100799402B1 (en) |
CN (1) | CN1523997B (en) |
AR (1) | AR029139A1 (en) |
AU (1) | AU2001273063A1 (en) |
BR (1) | BR0112101B1 (en) |
CA (1) | CA2413334C (en) |
CO (1) | CO5290308A1 (en) |
CU (1) | CU23536A3 (en) |
DE (1) | DE60142412D1 (en) |
DO (1) | DOP2001000197A (en) |
EC (1) | ECSP014106A (en) |
ES (1) | ES2344729T3 (en) |
HN (1) | HN2001000139A (en) |
IL (2) | IL153587A0 (en) |
MX (1) | MXPA03000046A (en) |
MY (1) | MY128629A (en) |
PE (1) | PE20020127A1 (en) |
SV (1) | SV2002000512A (en) |
TW (1) | TWI235063B (en) |
UY (1) | UY26805A1 (en) |
WO (1) | WO2002000243A2 (en) |
Families Citing this family (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8531276B2 (en) * | 2000-03-15 | 2013-09-10 | Logitech Europe S.A. | State-based remote control system |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
JP5057648B2 (en) * | 2002-09-26 | 2012-10-24 | 塩野義製薬株式会社 | Stabilized protein composition |
US20060099567A1 (en) * | 2004-04-08 | 2006-05-11 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
EP1737573A2 (en) * | 2004-04-08 | 2007-01-03 | Biomatrica, Inc. | Integration of sample storage and sample management for life science |
US7718622B2 (en) * | 2005-03-04 | 2010-05-18 | Dynavax Technologies Corporation | Compositions comprising structurally stable conjugate molecules |
EP2001500A4 (en) * | 2006-03-10 | 2010-07-28 | Dyax Corp | Formulations for ecallantide |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (en) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | USES OF DPP IV INHIBITORS |
EA030606B1 (en) | 2006-05-04 | 2018-08-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Methods of preparing a medicament comprising polymorphs |
WO2008150479A2 (en) * | 2007-06-01 | 2008-12-11 | Acologix, Inc. | High temperature stable peptide formulation |
PE20140960A1 (en) | 2008-04-03 | 2014-08-15 | Boehringer Ingelheim Int | FORMULATIONS INVOLVING A DPP4 INHIBITOR |
DE102008023820A1 (en) | 2008-05-08 | 2009-11-12 | Aicuris Gmbh & Co. Kg | An agent for the treatment and / or prophylaxis of an autoimmune disease and for the production of regulatory T cells |
BRPI0916997A2 (en) | 2008-08-06 | 2020-12-15 | Boehringer Ingelheim International Gmbh | DPP-4 INHIBITOR AND ITS USE |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
WO2010043566A2 (en) | 2008-10-17 | 2010-04-22 | Sanofi-Aventis Deutschland Gmbh | Combination of an insulin and a glp-1 agonist |
CA2761675A1 (en) * | 2009-05-11 | 2010-11-18 | Biomatrica, Inc. | Compositions and methods for biological sample storage |
US9707176B2 (en) | 2009-11-13 | 2017-07-18 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical composition comprising a GLP-1 agonist and methionine |
ES2855146T3 (en) | 2009-11-13 | 2021-09-23 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a GLP-1 agonist, an insulin and methionine |
ES2760917T3 (en) | 2009-11-27 | 2020-05-18 | Boehringer Ingelheim Int | Treatment of diabetic patients genotyped with DPP-IV inhibitors such as linagliptin |
JP6034781B2 (en) | 2010-05-05 | 2016-11-30 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination therapy |
US9376709B2 (en) | 2010-07-26 | 2016-06-28 | Biomatrica, Inc. | Compositions for stabilizing DNA and RNA in blood and other biological samples during shipping and storage at ambient temperatures |
EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
PT2611458T (en) | 2010-08-30 | 2016-12-16 | Sanofi Aventis Deutschland | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
PT2637694T (en) | 2010-11-12 | 2021-05-05 | Nektar Therapeutics | Conjugates of an il-2 moiety and a polymer |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
WO2012075379A2 (en) * | 2010-12-02 | 2012-06-07 | Oncolytics Biotech Inc. | Liquid viral formulations |
US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
PT2750699E (en) | 2011-08-29 | 2015-11-03 | Sanofi Aventis Deutschland | Pharmaceutical combination for use in glycemic control in diabetes type 2 patients |
TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
EP3685839A1 (en) | 2012-05-14 | 2020-07-29 | Boehringer Ingelheim International GmbH | Linagliptin for use in the treatment of albuminuria and kidney related diseases |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
CN103063829B (en) * | 2012-12-21 | 2015-01-14 | 杭州茂天赛科技有限公司 | Frozen stock solution |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
JP6661554B2 (en) | 2014-06-10 | 2020-03-11 | バイオマトリカ,インク. | Platelet stabilization at ambient temperature |
SG11201700629TA (en) | 2014-08-11 | 2017-02-27 | Delinia Inc | Modified il-2 variants that selectively activate regulatory t cells for the treatment of autoimmune diseases |
CN107206058A (en) | 2014-12-12 | 2017-09-26 | 赛诺菲-安万特德国有限公司 | Insulin glargine/lixisenatide fixed ratio preparaton |
TWI748945B (en) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | Treatment type 2 diabetes mellitus patients |
TW201705975A (en) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | Treatment of type 2 diabetes mellitus patients |
SG11201804776SA (en) | 2015-12-08 | 2018-07-30 | Biomatrica Inc | Reduction of erythrocyte sedimentation rate |
US20170204154A1 (en) | 2016-01-20 | 2017-07-20 | Delinia, Inc. | Molecules that selectively activate regulatory t cells for the treatment of autoimmune diseases |
JP2019517542A (en) | 2016-06-10 | 2019-06-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Combination of linagliptin and metformin |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
US11077172B2 (en) | 2016-11-08 | 2021-08-03 | Delinia, Inc. | IL-2 variants for the treatment of psoriasis |
CA3056630A1 (en) | 2017-03-15 | 2018-09-20 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
CA3064435A1 (en) | 2017-05-24 | 2018-11-29 | Pandion Therapeutics, Inc. | Targeted immunotolerance |
US10174091B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
AU2019246389A1 (en) | 2018-03-28 | 2020-08-27 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
BR112021023345A2 (en) | 2019-05-20 | 2022-02-01 | Pandion Operations Inc | Targeted immunotolerance in madcam |
CA3162705A1 (en) | 2019-12-17 | 2021-06-24 | Amgen Inc. | Dual interleukin-2 /tnf receptor agonist for use in therapy |
MX2022007754A (en) | 2019-12-20 | 2022-07-19 | Regeneron Pharma | Novel il2 agonists and methods of use thereof. |
US11633488B2 (en) | 2020-01-10 | 2023-04-25 | Bright Peak Therapeutics Ag | Modified IL-2 polypeptides and uses thereof |
KR102653906B1 (en) | 2020-01-14 | 2024-04-03 | 신테카인, 인크. | Biased IL2 mutein methods and compositions |
EP4161956A1 (en) | 2020-06-03 | 2023-04-12 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
TWI815194B (en) | 2020-10-22 | 2023-09-11 | 美商基利科學股份有限公司 | INTERLEUKIN-2-Fc FUSION PROTEINS AND METHODS OF USE |
JP2023549191A (en) * | 2020-11-13 | 2023-11-22 | 江蘇恒瑞医薬股▲ふん▼有限公司 | Pharmaceutical compositions containing human interleukin 2 variants or derivatives thereof and uses thereof |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0158487B1 (en) * | 1984-04-09 | 1991-08-28 | Takeda Chemical Industries, Ltd. | Stable composition of interleukin-2 |
JPS60215631A (en) * | 1984-04-09 | 1985-10-29 | Takeda Chem Ind Ltd | Interleukin-2 composition |
JPH0645551B2 (en) * | 1986-01-07 | 1994-06-15 | 塩野義製薬株式会社 | Interleukin-2 composition |
JPH0229016A (en) * | 1989-06-09 | 1990-01-31 | Alpine Electron Inc | Equalizer |
US5358708A (en) | 1993-01-29 | 1994-10-25 | Schering Corporation | Stabilization of protein formulations |
US5656730A (en) * | 1995-04-07 | 1997-08-12 | Enzon, Inc. | Stabilized monomeric protein compositions |
US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US5763401A (en) | 1996-07-12 | 1998-06-09 | Bayer Corporation | Stabilized albumin-free recombinant factor VIII preparation having a low sugar content |
US6509023B1 (en) * | 1997-07-31 | 2003-01-21 | Rhodia Chimie | Cosmetic composition comprising a functionalized polyorganosiloxane |
DZ2788A1 (en) * | 1998-05-15 | 2003-12-01 | Bayer Ag | Selective IL-2 agonists and antagonists. |
US6689353B1 (en) * | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
-
2000
- 2000-06-28 US US09/605,577 patent/US6689353B1/en not_active Expired - Lifetime
-
2001
- 2001-06-14 AR ARP010102841A patent/AR029139A1/en active IP Right Grant
- 2001-06-26 MY MYPI20013006A patent/MY128629A/en unknown
- 2001-06-26 DO DO2001000197A patent/DOP2001000197A/en unknown
- 2001-06-26 CO CO01050546A patent/CO5290308A1/en not_active Application Discontinuation
- 2001-06-27 ES ES01952296T patent/ES2344729T3/en not_active Expired - Lifetime
- 2001-06-27 IL IL15358701A patent/IL153587A0/en active IP Right Grant
- 2001-06-27 MX MXPA03000046A patent/MXPA03000046A/en active IP Right Grant
- 2001-06-27 EP EP01952296A patent/EP1370280B1/en not_active Expired - Lifetime
- 2001-06-27 WO PCT/US2001/020675 patent/WO2002000243A2/en active Application Filing
- 2001-06-27 AU AU2001273063A patent/AU2001273063A1/en not_active Abandoned
- 2001-06-27 EC EC2001004106A patent/ECSP014106A/en unknown
- 2001-06-27 DE DE60142412T patent/DE60142412D1/en not_active Expired - Lifetime
- 2001-06-27 CA CA2413334A patent/CA2413334C/en not_active Expired - Lifetime
- 2001-06-27 JP JP2002505024A patent/JP5522878B2/en not_active Expired - Lifetime
- 2001-06-27 KR KR1020027017859A patent/KR100799402B1/en active IP Right Grant
- 2001-06-27 SV SV2001000512A patent/SV2002000512A/en unknown
- 2001-06-27 BR BRPI0112101A patent/BR0112101B1/en not_active IP Right Cessation
- 2001-06-27 UY UY26805A patent/UY26805A1/en not_active IP Right Cessation
- 2001-06-27 CN CN018144454A patent/CN1523997B/en not_active Expired - Fee Related
- 2001-06-28 PE PE2001000639A patent/PE20020127A1/en not_active Application Discontinuation
- 2001-06-28 TW TW090115670A patent/TWI235063B/en not_active IP Right Cessation
- 2001-06-28 HN HN2001000139A patent/HN2001000139A/en unknown
-
2002
- 2002-12-23 IL IL153587A patent/IL153587A/en unknown
- 2002-12-24 CU CU20020334A patent/CU23536A3/en not_active IP Right Cessation
-
2012
- 2012-06-21 JP JP2012139913A patent/JP2012211166A/en active Pending
-
2014
- 2014-09-08 JP JP2014182175A patent/JP5989728B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2001273063A1 (en) | Stabilized interleukin 2 | |
AU2001262847A1 (en) | Language-understanding | |
AU2001254546A1 (en) | Aminopiperidines | |
AU2000267458A1 (en) | Hypercomputer | |
AU2001239310A1 (en) | Decahydro-isoquinolines | |
AU2001220246A1 (en) | Neckphone | |
AU2001231532A1 (en) | Improved interleukin 10 | |
AU2001258349A1 (en) | Bisacylguanidine | |
AU2001279754A1 (en) | Indoloquinazolinones | |
AU2001281965A1 (en) | Novel 6-phenylphenanthridines | |
AU2001258924A1 (en) | Microsatellite-aflp | |
AU3724701A (en) | Family 5 xyloglucanases | |
AU2001281921A1 (en) | Bdellosomes | |
AU2001246864A1 (en) | Hypotensors | |
AU2001245953A1 (en) | Oncogenic osteomalacia-related gene 1 | |
AU2001262711A1 (en) | Cytoprotectors | |
AU2001260192A1 (en) | Glycinamides | |
AU2001226668A1 (en) | Crankshaft-starter-generator | |
AU2002221623A1 (en) | Gene 4 | |
AU2001275014A1 (en) | Imidazoloisoquinolines | |
AU2001274750A1 (en) | Novel beta-hydroxyamides | |
AU2001239750A1 (en) | Haplotypes of the interleukin 15 gene | |
AU2001256287A1 (en) | 2-phenyl-2h-pyridazine-3-ones | |
AU2001256521A1 (en) | Golf-putters | |
AUPQ746000A0 (en) | X-band 2000 |